5 Best Stocks to Buy According to John Paulson

2. Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)

Paulson’s Stake Value: $735,532,000
Percentage of John Paulson’s 13F Portfolio: 16.89%
Number of Hedge Fund Holders: 48

Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) is a biotechnology company that emphasizes the discovery, development, and commercialization of medicines to cure autoimmune and severe inflammatory diseases. The company was founded in 2005 and ranks second on the list of 10 best stocks to buy according to John Paulson. Shares of Horizon rallied 68.57% in the last 12 months. 

On July 16, Piper Sandler analyst David Amsellem initiated a coverage on Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) with an “Overweight” rating and price target of $125.

Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) is another large-cap stock in Paulson & Co’s portfolio, in which the fund owns 7.99 million shares worth $735.53 million. Kurt Von Emster’s VenBio Select Advisor is the most significant stakeholder, with 9 million shares worth $828.36 million.

Carillon Tower Advisers, in their first quarter 2021 investor letter, mentioned Horizon Therapeutics Public Limited Company (NASDAQ: HZNP). Here is what the fund said:

“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing of late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product Tepezza, which is used in the treatment of thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”